Preparation of a liposomal delivery system and its in vitro release of rapamycin

Miao,Zhi‑Lin; Deng,Ying‑Jie; Du,Hong‑Yang; Suo,Xu‑Bin; Wang,Xiao‑Yu; Wang,Xiao; Wang,Li; Cui,Li‑Jie; Duan,Na

doi:10.3892/etm.2015.2201

Preparation of a liposomal delivery system and its in vitro release of rapamycin

Authors:
- Zhi‑Lin Miao
- Ying‑Jie Deng
- Hong‑Yang Du
- Xu‑Bin Suo
- Xiao‑Yu Wang
- Xiao Wang
- Li Wang
- Li‑Jie Cui
- Na Duan
View Affiliations

Affiliations: Heart Center, The People's Hospital of Liaoning Province, Shenyang, Liaoning 110016, P.R. China, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China, Dalian Medical University Graduate School, Dalian, Liaoning 116044, P.R. China
Published online on: January 22, 2015 https://doi.org/10.3892/etm.2015.2201
Pages: 941-946

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to prepare a liposomal delivery system for rapamycin and study its in vitro release characteristics. The results may provide a foundation for the further development of a liposomal delivery system for rapamycin and the establishment of a new active treatment method targeted towards the cellular components of atherosclerotic plaques. The ethanol injection method was used to prepare rapamycin‑containing liposomes. The formulation was optimized by orthogonal design, and the degree of rapamycin release by the liposomes was measured by the reverse dialysis method. Orthogonal testing showed that the optimum formulation had a phospholipid concentration of 4%, a phospholipid‑cholesterol mass ratio of 8:1, a drug‑lipid mass ratio of 1:20 and an aqueous phase pH of 7.4. Rapamycin‑containing liposomes with an encapsulation efficiency of 82.11±2.13% were prepared, and the in vitro release of rapamycin from the liposomes complied with a first‑order kinetic equation. In conclusion, the formulation was optimized, the prepared liposomes had a high rapamycin encapsulation rate and good reproducibility, and their in vitro release had a certain delayed‑release effect.

View Figures

View References

1	de Jager SC and Kuiper J: Vaccination strategies in atherosclerosis. Thromb Haemost. 106:796–803. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G and Abraham RT: Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 270:815–822. 1994. View Article : Google Scholar
3	Cheng-Lai A and Frishman WH: Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease. Am J Ther. 11:218–228. 2004. View Article : Google Scholar : PubMed/NCBI
4	Klugherz BD, Llanos G, Lieuallen W, et al: Stent-based delivery of sirolimus for the prevention of resrenosis. J Am Coll Cardiol. 35(Suppl 1): 58A2000.
5	Gallo R, Padurean A, et al: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 99:2164–2170. 1999. View Article : Google Scholar : PubMed/NCBI
6	Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T and Ahmad I: Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 59:177–187. 2005. View Article : Google Scholar
7	Li C and Deng Y: A novel method for the preparation of liposomes: freeze drying of monophase solutions. J Pharm Sci. 93:1403–1414. 2004. View Article : Google Scholar : PubMed/NCBI
8	Lu YP, Lasne C and Chouroulinkov I: Use of an orthogonal design method to study two-stage chemical carcinogenesis in BALB/3T3 cells. Carcinogenesis. 7:893–898. 1986. View Article : Google Scholar : PubMed/NCBI
9	Levy MY and Benita S: Drug release from submicronized O/W emulsion: a new in vitro kinetic evaluation model. Int J Pharm. 66:291990. View Article : Google Scholar
10	Rouf MA, Bilensoy E, Vural I and Hıncal AA: Determination of stability of sirolimus following exposure to different conditions. Eur J Pharm Sci. 32(Suppl): S462007.
11	Higuchi WI, Tzeng CS, Chang SJ, Chiang HJ and Liu CL: Estimation of cholesterol solubilization by a mixed micelle binding model in aqueous tauroursodeoxycholate:lecithin:cholesterol solutions. J Pharm Sci. 97:340–349. 2008. View Article : Google Scholar
12	Ravi PR, Ganga S and Saha RN: Design and in vitro evaluation of zidovudine oral controlled release tablets prepared using hydroxypropyl methylcellulose. Chem Pharm Bull (Tokyo). 56:518–524. 2008. View Article : Google Scholar
13	Lionberger RA, Raw AS, Kim SH, Zhang X and Yu LX: Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations. Pharm Res. 29:1110–1120. 2012. View Article : Google Scholar : PubMed/NCBI
14	Masaka T, Matsuda T, Li Y, et al: Synthesis of VIP-lipopeptide using a new linker to modify liposomes: Towards the development of a drug delivery system for active targeting. Chem Pharm Bull (Tokyo). 61:1184–1187. 2013. View Article : Google Scholar
15	Wang X, Lin Y, Zeng Y, Sun X, Gong T and Zhang Z: Effects of mycophenolic acid-glucosamine conjugates on the base of kidney targeted drug delivery. Int J Pharm. 456:223–234. 2013. View Article : Google Scholar : PubMed/NCBI
16	Pehlivan SB: Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm Res. 30:2499–2511. 2013. View Article : Google Scholar : PubMed/NCBI
17	Arias JL: Liposomes in drug delivery: a patent review (2007 - present). Expert Opin Ther Pat. 23:1399–1414. 2013. View Article : Google Scholar : PubMed/NCBI
18	Murakami M, Cabral H, Matsumoto Y, et al: Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med. 3:64ra22011. View Article : Google Scholar : PubMed/NCBI
19	Musacchio T and Torchilin VP: Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci (Landmark Ed). 16:1388–1412. 2011. View Article : Google Scholar
20	Roger M, Clavreul A, Venier-Julienne MC, Passirani C, Montero-Menei C and Menei P: The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials. 32:2106–2116. 2011. View Article : Google Scholar
21	Suo X, Deng Y and Hao A: Determination of lauroyl-indapamide in rat whole blood by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 819:191–196. 2005. View Article : Google Scholar : PubMed/NCBI
22	Torchilin VP, Narula J, Halpern E and Khaw BA: Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardlium. Biochem Biophys Acta. 1279:75–83. 1996. View Article : Google Scholar
23	Chen Y, Deng YJ and Hao YL: Surface modification of liposomes for cardiomyocytes targeting in vitro. Pharmazie. 60:238–240. 2005.PubMed/NCBI
24	Chen Y, Deng YJ, Hao YL, Hao AJ, Zhong HJ and Wang XM: Uptake of liposomes by cultured cardiomyocytes. Pharmazie. 60:844–848. 2005.PubMed/NCBI
25	Nag OK and Awasthi V: Surface engineering of liposomes for stealth behavior. Pharmaceutics. 25:542–569. 2013. View Article : Google Scholar
26	Paszko E and Senge MO: Immunoliposomes. Curr Med Chem. 19:5239–5277. 2012. View Article : Google Scholar : PubMed/NCBI
27	Shen J and Burgess DJ: In vitro dissolution testing strategies for nanoparticulate drug delivery systems: recent developments and challenges. Drug Deliv Transl Res. 3:409–415. 2013. View Article : Google Scholar : PubMed/NCBI